Informação sobre produto
- N-Cyclopropyl-4-[6-(2,3-difluoro-4-methoxyphenoxy)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide
BAY 12-17389 is a novel anticancer drug that inhibits the activity of CDK4 and CDK6. It is an imidazopyrazine derivative, which binds to the ATP-binding pocket of the enzyme, thereby preventing its activation. BAY 12-17389 has shown anticancer activity in animal models for skin cancer and bladder cancer. In vitro assays have demonstrated that BAY 12-17389 is effective at inhibiting proliferation of cultured cells from different types of human cancers. The effective dose for BAY 12-17389 is not yet known but it has been shown to be safe at doses as high as 2 µM.
Propriedades químicas
Consulta técnica sobre: 3D-EMC45853 BAY 12-17389
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
